Drugmaker Merck & Co., Inc. ( MRK
The Kenilworth, NJ-based compared reported second quarter net income of $752.4 million, or 24 cents per share, compared with $1.56 billion, or 74 cents per share, in the year-ago period.
Excluding multiple one-time items, however, adjusted profit was a much-higher 86 cents per share, and revenue nearly doubled from last year, to $11.35 billion.
On average, Wall Street analysts expected a smaller adjusted profit of 83 cents per share, albeit on slightly higher revenue of $11.45 billion.
Looking ahead, the company forecast full-year earnings of 82 cents to $1.16 per share, or $3.29 to $3.39 on an adjusted basis. Analysts currently expect a full-year adjusted profit of $3.37 per share.
Merck shares fell 71 cents, or -2%, in premarket trading Friday.
The Bottom Line
Shares of MRK have a 4.34% dividend yield, based on last night's closing stock price of $35.06. The stock has technical support in the $32-$33 price area. If the shares can firm up, we see overhead resistance around the $38 price level. We would remain on the sidelines for now.
Merck & Co., Inc. ( MRK ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com